Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ADXN | US
0
0%
Healthcare
Biotechnology
30/06/2024
13/03/2026
6.88
6.29
7.15
6.29
Addex Therapeutics Ltd a development-stage biopharmaceutical company discovers develops and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain anxiety and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot"Marie""Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva Switzerland."
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
42.4%1 month
57.8%3 months
65.3%6 months
101.5%-
-
0.77
0.00
0.00
-0.76
7.12
-
-11.07M
7.35M
7.35M
-
-780.14
-
-81.80
-126.29
0.27
1.15
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.73
Range1M
1.73
Range3M
4.14
Rel. volume
0.42
Price X volume
9.63K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| BioAtla Inc. | BCAB | Biotechnology | 0.1651 | 7.98M | -1.90% | n/a | 5.30% |
| Pulmatrix Inc | PULM | Biotechnology | 2.11 | 7.71M | -2.31% | n/a | 0.18% |
| ADTX | ADTX | Biotechnology | 1.82 | 7.68M | -37.02% | n/a | 122.46% |
| Synlogic Inc | SYBX | Biotechnology | 0.61 | 7.13M | 1.67% | n/a | 0.00% |
| Hoth Therapeutics Inc | HOTH | Biotechnology | 1.03 | 7.11M | -3.74% | n/a | 0.44% |
| CollPlant Holdings Ltd | CLGN | Biotechnology | 0.585 | 6.70M | -1.18% | n/a | 0.00% |
| Purple Biotech Ltd | PPBT | Biotechnology | 4.1 | 6.46M | 6.77% | n/a | 0.89% |
| KPRX | KPRX | Biotechnology | 2.09 | 6.21M | -2.79% | 0.21 | 0.25% |
| NovaBay Pharmaceuticals Inc | NBY | Biotechnology | 1.21 | 5.91M | -4.72% | n/a | -325.77% |
| Moleculin Biotech Inc | MBRX | Biotechnology | 2.04 | 5.80M | -0.49% | n/a | 3.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.79 | 5.77M | -0.52% | n/a | 204.46% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.3803 | 3.62M | -3.79% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.39 | 1.32M | -0.42% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.76 | - | Cheaper |
| Ent. to Revenue | 7.12 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.77 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 65.34 | - | Par |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 7.35M | - | Emerging |